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Impact of Prevnar (PCV13) vaccine recommenda�ons in pediatric and
immunocompetent adults 65 years and older: What are the beneﬁts and risks?
James E. Watkins, PharmD Candidate 2020; Anne Marie Thibodeaux, PharmD, MPH; John C. Darnell, PharmD, BCACP  
BACKGROUND KEY QUESTIONS
REFERENCES
DISCUSSION
• 2000: PCV7 becomes the ﬁrst FDA approved 
pneumococcal vaccine for pediatrics 
• 2010: PCV13 recommended in pediatrics
• 2014: PCV13 recommended in immunocompetent 
adults 65+
• 2018: CDC looked at data since 2014 recommendation
• 2019: PCV13 now shared clinical decision-making
~4% OF ALL-CAUSE PNEUMONIA IS CAUSED BY THE PCV13-TYPE
1. How much did the IPD incidence change among 
adults 65+ since the 2010 pediatric PCV13 
recommendation?
2. How much did the IPD incidence change among 
adults 65+ since the 2014 adult PCV13 
recommendation?
3. How much was mortality impacted among adults 
65+ since the 2014 PCV13 recommendation ?
4. How much does PCV13-type pneumonia account 
for all-cause pneumonia?
CONTEXT
Immunocompetent Immunocompromised
• Chronic heart disease
• Chronic lung disease 
• Chronic liver disease
• Poorly controlled 
diabetes
• Current cigare�e smoker
• Alcohol used disorder
• Chronic renal failure
• Nephro�c syndrome
• Iatrogenic 
immunosuppression 
• HIV
• Cochlear implants
• CSF leaks
• Generalized malignancy
• Hodgkin Disease
• Leukemia, lymphoma, 
mul�ple myeloma 
• Solid organ transplant
• Congenital or acquired 
asplenia
• Sickle cell disease
IPD: Invasive Pneumococcal Disease
How much did the IPD incidence change among adults 65+ since the 
2014 PCV13 recommendation?
Key Point: No change in IPD incidence since 2014
How much was mortality impacted among adults 65+ since the 2014 
adult PCV13 recommendation?
Key Point: No changes in case fatality ratio 
How much does PCV13-type pneumonia account for all-cause 
pneumonia?
Key Point: PCV13-type pneumonia accounts for ~4% of all-cause pneumonia
June 2014—May 2015
Incidence per 100,000 
(95% CI)
June 2015—May 2016
Incidence per 100,000 
(95% CI)
All-Cause CAP 2412 (2317, 2511) 2080 (1992, 2172)
PCV13-Type CAP 112 (93, 135) 76 (61, 96)
% of CAP Caused 
by PCV13 Serotype 4.6% 4.7%
KEY QUESTION #1 KEY QUESTION #2
How much did the IPD incidence change among 
adults 65+ since the 2010 pediatric PCV13 recommendation?
Key Point: Three-fold reduction in PCV13-type IPD after 
PCV13 introduction for children 
ANNUAL NUMBER NEEDED TO VACCINATE (NNV) AMONG ADULTS 65+
IPD:
• PCV13 prevents 1 case for every 26,300 healthy seniors immunized per year
OUTPATIENT PNEUMONIA:
• PCV13 prevents 1 case for every 2,600 healthy seniors immunized per year
SHARED DECISION-MAKING
SAFETY:
• NO safety concerns with PCV13
• Doesn’t seem to provide much beneﬁt
HERD IMMUNITY:
• Infec�ons prevented by PCV13 are now less common
• Likely due to years of vaccinating children with PCV13
OTHER WAYS TO PROTECT PATIENTS:
• Recommend annual inﬂuenza vaccines
• Reinforce good hand hygiene
• Maintain healthy lungs
GENERAL VACCINE SCHEDULE
INFANTS:
• PCV13 as 4-dose series at 2, 4, 6, and 12-15 months
AGES 19-64:
• Healthy: Vaccine NOT recommended un�l 65
• Increased risk of pneumococcal disease: 1 dose of PPSV23
• Increased risk for meningitis: PCV13, then PPS23 8 weeks later
• Immunocompromised: PCV13, then PPSV23 8 weeks later
ADULTS 65+:
• Immunocompetent: Shared Decision-Making
• Immunocompromised: PCV13, then PPSV23 8 weeks later
KEY QUESTION #3 KEY QUESTION #4
1. Centers for Disease Control (CDC) and Prevention. Recommended adult immunization schedule for ages 19 years or older. 
https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf
 Accessed November 10, 2019
2. Matanock MD, A. Considerations for PCV13 use among adults >65 years old and a summary of the evidence to 
recommendations framework. Lecture presented at: Advisory Committee on Immunization Practices (ACIP); 
June 2019; Atlanta, GA 
